newsfilter
← Latest News
GlobeNewswire·

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability